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ABSTRACT
Mechanistic target of rapamycin complex 1 (MTORC1) and polo like kinase 1 (PLK1) are major drivers of
cancer cell growth and proliferation, and inhibitors of both protein kinases are currently being
investigated in clinical studies. To date, MTORC10s and PLK10s functions are mostly studied separately, and
reports on their mutual crosstalk are scarce. Here, we identify PLK1 as a physical MTORC1 interactor in
human cancer cells. PLK1 inhibition enhances MTORC1 activity under nutrient sufﬁciency and in starved
cells, and PLK1 directly phosphorylates the MTORC1 component RPTOR/RAPTOR in vitro. PLK1 and
MTORC1 reside together at lysosomes, the subcellular site where MTORC1 is active. Consistent with an
inhibitory role of PLK1 toward MTORC1, PLK1 overexpression inhibits lysosomal association of the PLK1-
MTORC1 complex, whereas PLK1 inhibition promotes lysosomal localization of MTOR. PLK1-MTORC1
binding is enhanced by amino acid starvation, a condition known to increase autophagy. MTORC1
inhibition is an important step in autophagy activation. Consistently, PLK1 inhibition mitigates autophagy
in cancer cells both under nutrient starvation and sufﬁciency, and a role of PLK1 in autophagy is also
observed in the invertebrate model organism Caenorhabditis elegans. In summary, PLK1 inhibits MTORC1
and thereby positively contributes to autophagy. Since autophagy is increasingly recognized to contribute
to tumor cell survival and growth, we propose that cautious monitoring of MTORC1 and autophagy
readouts in clinical trials with PLK1 inhibitors is needed to develop strategies for optimized (combinatorial)
cancer therapies targeting MTORC1, PLK1, and autophagy.
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PLK1 (polo like kinase 1) is a ubiquitously expressed serine/threo-
nine protein kinase, which is widely recognized as an oncogene
that drives cellular proliferation by promoting mitosis and cytoki-
nesis.1-3 The 5 polo like kinase (PLK) family members PLK1 to 5
all contain a polo-box domain that regulates their kinase activity
and subcellular localization.1-3 PLK1 is the best-described PLK
protein, and is frequently used as a tumor marker, as high PLK1
expression correlates with poor prognosis in cancer.4 PLK1 inhib-
itors, such as BI2536, compete with adenosine triphosphate
(ATP) for its binding to the catalytic domain of PLK1.5 Long-
term PLK1 inhibition arrests cells in prometaphase, and thus
PLK1 inhibitors are investigated as antimitotic agents for cancer
treatment.1,6,7 MTOR (mechanistic target of rapamycin) is
another serine/threonine protein kinase that promotes cellular
growth and is also often targeted in cancer therapy.8,9 Although
both PLK12,3 and MTOR10 are conserved in invertebrates and
mammals, little is known about their crosstalk andmutual regula-
tion of common downstream processes, as well as the implica-
tions thereof for cancer therapies.
The nutrient sensor MTOR is activated by metabolic stimuli,
including amino acids, growth factors (e.g., insulin), and energy
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sufﬁciency.10-12 MTOR acts in 2 structurally and functionally
distinct multiprotein complexes, MTOR complex 1 (MTORC1)
and MTORC2.10,12 RPTOR/RAPTOR (regulatory associated
protein of MTOR complex 1) is a core component of
MTORC1,10,12 which is a central controller of cellular growth
and survival. Consistently, MTORC1 is dysregulated in many
cancer types,8 and several compounds for pharmacological
MTORC1 inhibition are investigated as cancer therapeutics.8,9
The MTORC1-speciﬁc allosteric inhibitor rapamycin and its
analogs (rapalogs) are already approved for the treatment of
several tumor entities.9 The more recently developed ATP-ana-
log MTOR inhibitors, such as Torin113 and its derivatives, are
currently tested in clinical studies.9 They target both MTOR
complexes, and also inhibit MTORC1 functions which are
insensitive to rapamycin.13 Amino acid- and growth factor-
induced signaling pathways converge at the lysosomes to syner-
gistically activate MTORC1.11 MTORC1 activation by amino
acids requires RAG GTPase-mediated MTORC1 translocation
to lysosomes.11,14,15 Conversely, loss of lysosomal MTORC1
association mediates MTORC1 inhibition upon amino acid
withdrawal.16 At the lysosome, MTORC1 encounters the small
GTPase Ras homolog enriched in brain (RHEB),11,17 which
activates MTORC1 downstream of the INSR (insulin recep-
tor)-phosphoinositide 3-kinase-AKT signaling axis.10,11,18
RHEB is inhibited by the heteromeric TSC1-TSC2 (tuberous
sclerosis 1 and 2) complex, which acts as a GTPase-activating
protein (GAP) on RHEB. MTORC1 phosphorylates several
substrates19 that mediate its anabolic outcomes. Among them
is RPS6KB (p70)/p70-S6K (ribosomal protein S6 kinase B
70 kDa) which is phosphorylated at threonine 389 (T389) by
MTORC1.10,18,20 In turn, RPS6KB (p70) activates protein syn-
thesis by promoting expression of ribosomal components,21
and by phosphorylating translation initiation factors and com-
ponents of the ribosomal machinery, including RPS6 (ribo-
somal protein S6).19 Little is known about PLK10s role in the
MTORC1 pathway. Even though several studies correlate PLK1
inhibition with either decreased22-25 or increased26 RPS6KB
(p70) or RPS6 phosphorylation, a clear functional interaction
between PLK1 and MTORC1 has so far not been reported.
Thus, it is unknown whether PLK1 regulates phosphorylation
of MTORC1 substrates indirectly or directly, i.e., by physically
acting on MTORC1.
MTORC1 promotes cellular growth by inducing anabolic
processes including protein synthesis, and by inhibiting cata-
bolic processes.10,19 Conversely, MTORC1 inhibition dere-
presses catabolic processes to promote cellular survival, e.g.,
when nutrients are scarce.10 The best-described catabolic pro-
cess inhibited by MTORC1 is autophagy, and this MTORC1
function is conserved from yeast and invertebrates such as Cae-
norhabditis elegans27 (C. elegans) to mammals.28 Autophagy is
tightly balanced to maintain cellular homeostasis and fuel cells
with nutrients and metabolite intermediates under nutrient suf-
ﬁciency and deprivation29 via degradation of proteins, lipids,
and organelles in the lysosomes.28,30 Macroautophagy (from
here on referred to as autophagy) is to date the best-character-
ized type of autophagy.30 During autophagy, double-membrane
vesicles called autophagosomes are formed which fuse with late
endosomes or lysosomes to form autolysosomes, in which the
degradation of the sequestered material takes place.30,31 In the
context of cancer, autophagy gains growing attention as auto-
phagy contributes to the elimination of tumor cells, but also
promotes tumor survival.32-34 Consequently, both autophagy
inhibitors, such as chloroquine,35 and autophagy activators,
e.g., proteasome and MTORC1 inhibitors,33,34 are currently
investigated in clinical trials. Of note, ATP-analog MTOR
inhibitors such as Torin1 enhance autophagy more effectively
than rapalogs, as ATP analogs block autophagy-inhibiting
MTORC1 functions that are rapamycin resistant.13 Autophagy
is also regulated by multiple MTORC1-independent cues.28 For
example, during mitosis autophagy is inhibited in an
MTORC1-independent manner.36,37 Links of PLK1 with auto-
phagy are poorly explored. PLK1 is known to localize to centro-
somes, kinetochores, and the mitotic spindle,2 and PLK1
expression is increased during mitosis.38 During this cell cycle
phase PLK1 has been suggested to contribute to autophagy
inhibition.39,40 As PLK1 research mostly focuses on mitotic
cells, it is unknown whether PLK1 affects autophagy in inter-
phase cells and which signaling networks might mediate such
effects. Such knowledge would broaden the range of application
of PLK1 inhibitors speciﬁcally to tumors that display low
mitotic rates,41 and/or require autophagy for cellular growth
and survival.42 It would also reveal potential effects of PLK1
inhibitors on MTOR and autophagy networks that may be rele-
vant for therapy outcome. Therefore, we analyzed in the pres-
ent study whether and what type of crosstalk exists between
PLK1, MTORC1, and autophagy in nonmitotic cancer cells.
We describe here a novel nonmitotic function of PLK1. We
identify PLK1 as a physical interactor of MTORC1, whose scaffold
component RPTOR is a direct PLK1 substrate in vitro. We ﬁnd
that PLK1 inhibition leads to hyperphosphorylation of the
MTORC1 substrate RPS6KB (p70). PLK1 resides with MTORC1
at lysosomes, a localization hitherto unknown for PLK1; and the
PLK1-MTORC1 complex colocalizes with and physically binds
LAMP2 (lysosomal-associated membrane protein 2). Consistent
with an inhibitory function of PLK1 towardMTORC1, overexpres-
sion of active PLK1 detaches the PLK1-MTORC1 complex from
the lysosomes, and PLK1 inhibition increases MTOR localization
at lysosomes. In keeping with this, PLK1 inhibition mitigates auto-
phagy in both the invertebrate model organism C. elegans, and in
mammalian cells, where autophagy is regulated in an MTORC1-
dependent manner. In conclusion, PLK1 positively contributes to
autophagy via inhibition of MTORC1 under nutrient sufﬁciency
and starvation. Our ﬁndings highlight the importance of carefully
monitoring PLK1-, MTOR-, and autophagy- activities in clinical
studies, to identify leads for cancer therapy design.
Results
PLK1 physically interacts with MTOR and RPTOR
We have recently analyzed the MTOR interactome by quantita-
tive proteomics.43 In this study,43 we puriﬁed endogenous
MTOR kinase by immunoprecipitation (IP) from the cervical
cancer cell line HeLa, and analyzed MTOR IPs versus mock
IPs, conducted with a nonspeciﬁc control IgG. We reanalyzed
those data here, and found that PLK1 was speciﬁcally identiﬁed
by tandem mass spectrometry in MTOR IPs for 2 out of 3 bio-
logical replicates (Schwarz et al, Table S443) with 6 peptides
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Figure 1. PLK1 binds and phosphorylates MTORC1, and PLK1 inhibition activates MTORC1 in interphase cells. (A) HeLa cells were cultured in full medium. Immunoprecip-
itation (IP) was performed with PLK1 and control (mock) antibodies. Samples were analyzed by immunoblotting. Data shown are representative of n D 4 independent
experiments. (B) HeLa cells were starved for 1 h for amino acids and growth factors, stimulated with amino acids and insulin for 35 min and treated with the PLK1 inhibi-
tor BI2536 for 30 min, as indicated. Samples were analyzed by immunoblotting. Data shown are representative of n D 3 independent experiments. (C) Quantiﬁcation of
data shown in (B). Ratio of RPS6KB (p70) phospho-(T389)/RPS6KB (p70) was calculated for n D 3 independent experiments. Data are normalized to 1 for the amino acid-
and insulin-stimulated control condition, and represented as mean § SEM. A one-way ANOVA followed by the Bonferroni multiple comparison test was applied; ns, non-
signiﬁcant; , P  0.01. (D) PLK1 (shPLK1) or control (shControl) shRNA HeLa cells were starved for amino acids and growth factors for 1 h, and stimulated with amino
acids and insulin for 30 min. Samples were analyzed by immunoblotting without removal of the mitotic cells. Data shown are representative of nD 3 independent experi-
ments. (E) Quantiﬁcation of data shown in (D). Ratio of RPS6KB (p70) phospho-(T389):RPS6KB (p70) was calculated for n D 3 independent experiments. Data are normal-
ized to 1 for the amino acid- and insulin-stimulated shControl condition, and represented as mean § SEM. A one-way ANOVA followed by the Bonferroni multiple
comparison test was applied; ns, nonsigniﬁcant. (F) RPTOR shRNA (shRPTOR) or shControl HeLa cells were arrested in mitosis by nocodazole treatment. Samples were ana-
lyzed by immunoblotting. Data shown are representative of n D 3 independent experiments. (G) PLK1 (shPLK1) or control (shControl) shRNA HeLa cells were starved for
amino acids and growth factors for 16 h and stimulated with amino acids and insulin for 35 min. Mitotic cells were removed by shake-off. Samples were analyzed by
immunoblotting. Data are representative of n D 4 independent experiments. (H) Quantiﬁcation of data shown in (G). Ratio of RPS6KB (p70) phospho-(T389):RPS6KB (p70)
was calculated for n D 4 independent experiments. Data are normalized to 1 for the amino acid- and insulin-stimulated shControl condition and represented as mean §
SEM. A one-way ANOVA followed by the Bonferroni multiple comparison test was applied; ns, nonsigniﬁcant; , P  0.01. (I) HeLa cells were treated with BI2536 and/or
Torin1 as indicated, and stimulated as described in (B). Samples were analyzed by immunoblotting. Data shown are representative of n D 3 independent experiments. (J)
Quantiﬁcation of data shown in (I). Ratio of RPS6KB (p70) phospho-(T389):RPS6KB (p70) was calculated for n D 3 independent experiments. Data are normalized to 1 for
control condition (no Torin1, no BI2536), and represented as mean § SEM. A one-way ANOVA followed by the Bonferroni multiple comparison test was applied; ns, non-
signiﬁcant; , P  0.01. (K) PLK1 kinase assay. HA-RPTOR was immunopuriﬁed from HeLa cells. An unspeciﬁc IgG antibody was used as negative control. All samples
were dephosphorylated before adding them to the kinase reaction with recombinant PLK1. Data shown are representative of n D 3 independent experiments. IP, immu-
noprecipitation; IB, immunoblot; KA, kinase assay. (L) Quantiﬁcation of data shown in (K) for n D 3 independent experiments. Data are normalized to 1 for HA-RPTOR
phosphorylation by PLK1. Data are represented as mean § SEM. A one-way ANOVA followed by the Bonferroni multiple comparison test was applied; ns, nonsigniﬁcant;
, P  0.01. (B, C, D, E, G, H, I) aa, amino acids; ins, insulin.
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and a sequence coverage of 11% (Fig. S1A). Annotated MS1
and fragment spectra for one of the PLK1 peptides are shown
in Fig. S1B and S1C. Physical interaction of PLK1 with MTOR
has not been reported previously. To validate this ﬁnding, we
performed PLK1 and mock IPs and analyzed them by immuno-
blotting (Fig. 1A, S1D). TSC2 and the MTORC2 component
RICTOR (RPTOR-independent companion of MTOR complex
2) were speciﬁcally detected in PLK1 IPs, serving as positive
controls, as interaction of TSC2 and RICTOR with PLK1 has
been shown earlier.23,44 Of note, we also speciﬁcally detected
MTOR and the MTORC1 component RPTOR in the PLK1 IP,
but not in the mock IP (Fig. 1A). To test if RPTOR is required
for PLK1-MTORC1 binding, we immunoprecipitated PLK1
from lysates of stably transduced HeLa cells with doxycycline-
inducible expression constructs for short hairpin RNAs target-
ing RPTOR (shRPTOR),45 or harboring a nontargeting
sequence (shControl). PLK1 bound MTOR to the same extent
in shRPTOR or shControl knockdown cells (Fig. S1E, S1F), sug-
gesting that PLK1 physically binds MTORC1 via MTOR.
PLK1 inhibits MTORC1 in nonmitotic cells
Next, we investigated whether PLK1 inﬂuences MTORC1 activ-
ity. We tested this ﬁrst upon MTORC1 activation with amino
acids and insulin. To inhibit PLK1, we treated HeLa cells for
30 min with the ATP-competitive PLK1 inhibitor BI2536.5 We
combined the PLK1 inhibitor treatment with amino acid and
insulin stimulation, and analyzed phosphorylation of RPS6KB
(p70) at T389 as a bona ﬁde readout for MTORC1 activity. As
expected, immunoblotting showed that amino acid and insulin
stimulation increased RPS6KB (p70) T389 phosphorylation, con-
sistent with MTORC1 activation (Fig. 1B, ﬁrst vs third lane).
Treatment with the PLK1 inhibitor BI2536 further enhanced
RPS6KB (p70) T389 phosphorylation signiﬁcantly (Fig. 1B, third
vs fourth lane; 1C). Thus, PLK1 inhibition leads to RPS6KB (p70)
hyperphosphorylation at T389 upon stimulation with amino
acids and insulin, suggesting that PLK1 inhibits MTORC1.
To conﬁrm this result by another mode of PLK1 inhibition
and to control for possible off-target effects of the PLK1 inhibi-
tor BI2536, we next inhibited PLK1 by RNA interference
(RNAi). To this end, we stably transduced HeLa cells with
doxycycline-inducible expression constructs for shRNAs tar-
geting PLK1 (shPLK1), or a nontargeting sequence (shControl).
Knockdown was induced by doxycycline treatment for 2 d. Sur-
prisingly, we observed no change in RPS6KB (p70) T389 phos-
phorylation in shPLK1 as compared with shControl cells
(Fig. 1D, E). This seemed contradictory to the increase in
RPS6KB (p70) phosphorylation at T389 that we observed upon
BI2536 treatment (Fig. 1B, C).
A main difference between BI2536- versus shPLK1-treated
cells was that the treatment with the inhibitor was done for a
brief interval (i.e., 30 min), whereas shPLK1 treatment was per-
formed for 2 d, which was required to achieve efﬁcient PLK1
knockdown. During these 2 d, we observed an increasing
amount of rounded and detached cells, probably due to elevated
numbers of mitotic cells, as long-term PLK1 inhibition leads to
mitotic arrest.46,47 We thus hypothesized that the difference in
RPS6KB (p70) T389 phosphorylation in shPLK1- versus
BI2536-treated cells could result from a larger fraction of
mitotic cells in shPLK1 cultures, or from differing (off-target)
effects during shPLK1 or BI2536 treatment. To test the ﬁrst
possibility directly, we analyzed if mitotic markers were
increased in shPLK1- and/or BI2536-treated cells. In shPLK1-
treated cells, we observed increased phosphorylation of the
mitotic marker H3F3/histone H3 (H3 histone family member
3) at serine 10 (S10), and decreased levels of the G1/S phase
marker CCNE1 (cyclin E1), indicative of an increased mitotic
cell fraction in shPLK1 cultures (Fig. 1D). In contrast, short-
term treatment with the PLK1 inhibitor BI2536 did not lead to
an apparent increase in H3F3 S10 phosphorylation (Fig. S2A).
As a positive control, the H3F3 phospho-(S10) antibody was in
parallel used to detect a cell lysate of mitotic cells (Fig. S2A),
and showed a strong signal. In agreement with earlier stud-
ies,3,46,47 long-term overnight BI2536 treatment enhanced H3F3
phosphorylation at S10 (Fig. S2B). Thus, we conclude that
short-term BI2536 treatment failed to cause a detectable shift in
cell cycle distribution, whereas long-term shPLK1 induction
did. This may be the reason for the observed differences in
MTORC1 signaling between these 2 experimental setups.
To further test this, we aimed to separate effects directly
mediated by PLK1 from its indirect, mitotic arrest-related
effects. For this purpose, we ﬁrst analyzed RPS6KB (p70) phos-
phorylation in mitotic versus asynchronous cell cultures, with
or without MTORC1 inhibition by shRPTOR (Fig. 1F). We
arrested cells in prometaphase by nocodazole treatment, fol-
lowed by a mitotic shake-off to enrich for mitotic cells. Immu-
noblot analysis showed that PLK1 levels were increased in
nocodazole plus shake-off-treated cells, indicative of a mitotic
arrest.38 Phosphorylation of the p70 isoform RPS6KB (p70) at
T389 was observed in asynchronous cells, but not in cells with
mitotic arrest, indicating that MTORC1 is inactive in mitotic
cells (Fig. 1F). Interestingly, phosphorylation of the p85 iso-
form RPS6KB (p85) at T41248 [RPS6KB (p85) phospho-
(T412), which is detected by the same antibody as RPS6KB
(p70) phospho-(T389) and thus appears at a higher molecular
weight in the same blot] was enhanced in mitotically arrested
cells compared with nonarrested cells (Fig. 1F, ﬁrst vs. second
lane). This induction of phospho-RPS6KB (p85) at T412 possi-
bly explains earlier reports on MTORC1 activation in mitosis.49
In contrast, T412 phosphorylation of RPS6KB (p85) in nocoda-
zole-arrested cells was not inhibited by shRNA-mediated
knockdown of the MTORC1 component RPTOR (Fig. 1F,
fourth vs second lane), indicating that a kinase other than
MTOR as member of MTORC1 mediates this event. In con-
trast, shRPTOR did reduce the signal for phospho-RPS6KB
(p70) at T389 in asynchronous cells (Fig. 1F, ﬁrst vs third lane).
Thus, the absence of phospho-RPS6KB (p70) signal at T389 in
prometaphase-arrested cells suggests that MTORC1 is inhibited
in mitosis (Fig. 1F, second and fourth lane), which is in line
with previous ﬁndings.50 This supports our hypothesis that an
increase in the amount of mitotic cells in a culture, as observed
after PLK1 knockdown, may mask MTORC1 activation in the
nonmitotic cell fraction in the same culture.
To test this, we combined PLK1 knockdown with removal of
mitotic cells by shake-off. The removal of the mitotic cells was efﬁ-
cient, as evidenced by the decline in H3F3 S10 phosphorylation in
cultures after shake-off, compared with those without shake-off
(Fig. S2C, fourth vs. third lane). In the nonmitotic cells that
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remained in the culture after shake-off, PLK1 knockdown did sig-
niﬁcantly increase RPS6KB (p70) phosphorylation at T389 in
response to amino acid and insulin stimulation (Fig. 1G, H) to a
similar extent as BI2536 (Fig. 1B, C). Thus, both BI2536 and
shPLK1 treatments in nonmitotic cells yielded qualitatively and
quantitatively similar results, namely RPS6KB (p70) phospho-
(T389) induction. This suggests that PLK1 acts to inhibit
MTORC1 in nonmitotic cells. To test whether enhanced RPS6KB
(p70) phospho-(T389) in PLK1-inhibited cells is consistent with
MTORC1 activation, we combined PLK1 inhibition by BI2536
with MTOR inhibition by Torin1.13 Torin1 reduced RPS6KB
(p70) T389 phosphorylation both in control and BI2536-treated
cells (Fig. 1I, J), consistent with the notion that increased RPS6KB
(p70) phosphorylation at T389 in PLK1-inhibited cells is mediated
byMTOR.
Taken together, RPS6KB (p70) was hyperphosphorylated at
T389 when PLK1 was blocked pharmacologically or through
shRNA in nonmitotic cells. This suggests that PLK1 inhibits
MTORC1 and limits the extent of RPS6KB (p70) T389 phosphory-
lation in response to nutrients and insulin in interphase cells.
PLK1 phosphorylates the MTORC1 component
RPTOR in vitro
We found that PLK1 physically interacts with MTOR and its
speciﬁc binding partner RPTOR (Fig. 1A), and that PLK1 inhi-
bition activates MTORC1 in amino acid- and insulin-stimu-
lated cells (Fig. 1B, G). Therefore, we next tested whether
MTORC1 can function as a direct PLK1 substrate in vitro. The
MTORC1 component RPTOR acts as a scaffold for the binding
of MTORC1’s substrates10 and is required for MTORC1 activ-
ity.51,52 RPTOR is targeted by several kinases that signal to
MTORC1,10 for example, AMPK (AMP-activated protein
kinase)10 and RPS6KA1/RSK (ribosomal protein S6 kinase
A1).53 To test whether PLK1 is also capable of phosphorylating
RPTOR, we overexpressed and immunopuriﬁed HA-tagged
RPTOR from HeLa cells and used it as a substrate for in vitro
kinase assays with recombinant PLK1 and 33P-labeled ATP
(Fig. 1K). We detected incorporation of 33P at the molecular
weight of HA-RPTOR, and this signal was reduced by the
PLK1 inhibitor BI2536 (Fig. 1K, L). Thus, the observed HA-
RPTOR phosphorylation was PLK1-speciﬁc. The MTOR inhib-
itor Torin1 did not signiﬁcantly reduce the radioactive HA-
RPTOR signal (Fig. 1K, L), suggesting that MTOR background
activity does not contribute to the signal. As a negative control
we omitted either PLK1 or HA-RPTOR from the in vitro kinase
reaction. In both cases, no radioactive signal was detected at the
molecular weight of HA-RPTOR (Fig. 1K, ﬁrst and third lane),
showing that the signal is RPTOR speciﬁc and requires the
presence of PLK1. Thus, we conclude that PLK1 can directly
phosphorylate RPTOR in vitro.
PLK1 resides with MTORC1 at lysosomes, and active PLK1
decreases lysosomal association of the PLK1-MTORC1
complex
Since PLK1 binds and can directly phosphorylate MTORC1, at
least in vitro, we next asked in which common subcellular
compartment they reside. In line with its function as a mitotic
regulator, PLK1 localizes to multiple mitosis-speciﬁc structures,
including centrosomes, kinetochores, and the spindle mid-
zone,2,3 but also to the Golgi.54 Lysosomal localization is well
described to be required for MTORC1 activation by amino
acids and insulin,14,15 although MTOR localizes also to various
other compartments.17,55,56 Localization of PLK1 to the lyso-
some has to the best of our knowledge so far not been reported.
To test whether in nonmitotic cells PLK1 resides with
MTORC1 at lysosomes, we ﬁrst analyzed the localization of
PLK1, MTOR and the lysosomal marker LAMP2 by immuno-
ﬂuorescence (IF) in unsynchronized HeLa cells (Fig. 2A, B).
Consistent with MTOR’s known localization at lysosomes,14
there was a strong overlap of MTOR and LAMP2 staining
(Fig. 2A). In addition, PLK1 and MTOR colocalized with each
other in a lysosomal pattern (Fig. 2B), suggesting that they
reside together at a common subcellular site. We tested the
speciﬁcity of the PLK1 antibody in mitotic metaphase and ana-
phase cells, where it detected PLK1 at the mitotic spindle, as
reported57 (Fig. 2C). It was not experimentally possible to per-
form PLK1 and LAMP2 costaining as the antibodies against
both PLK1 and LAMP2 were raised in mice and antibodies
suitable for IF from other species were not available. To further
test whether PLK1 localizes to lysosomes, we used sucrose gra-
dients to fractionate cell lysates from unsynchronized HeLa cell
cultures. The mitotic marker H3F3 phospho-(S10) was unde-
tectable in these cultures, as compared with lysates from mitoti-
cally arrested HeLa cells (Fig. 2D), suggesting that mitotic cells
in the unsynchronized cultures were below the detection
threshold. As expected, distribution of endogenous PLK1 par-
tially overlapped with fractions that contained the nuclear
markers LMNA (lamin A/C) and H3F3. However, much stron-
ger signals for PLK1 were found in fractions that were positive
for the lysosomal marker LAMP2, MTOR, and RPTOR
(Fig. 2E, F). Thus, PLK1 coresided with MTOR and RPTOR in
the lysosomal fractions, suggesting that PLK1 may bind to lyso-
somes. To test whether PLK1 indeed physically interacts with
lysosomal components, we analyzed PLK1 IPs with a LAMP2
antibody. Indeed, the lysosomal marker LAMP2 and the
MTORC1 component RPTOR (positive control, see also
Fig. 1A) were speciﬁcally detected in PLK1 IPs, but not in
mock IPs (Fig. 2G), suggesting that PLK1 resides together with
MTORC1 at lysosomes.
As our previous data (Fig. 1B, C, G to J) suggested that PLK1
inhibits MTORC1, and lysosomal relocalization is an important
mode of MTORC1 regulation,14-16,58 we next tested whether
PLK1 induction alters LAMP2-association of the PLK1-
MTORC1 complex. To this end, we transfected cells with
MYC-tagged, wild-type PLK1 [MYC-PLK1 (WT)]38 or an
empty-control vector, performed PLK1 IPs, and detected
LAMP2, MTOR and RPTOR by immunoblotting (Fig. 2H).
MYC-PLK1 (WT) overexpression did not alter the endogenous
MTOR, RPTOR, or LAMP2 levels in the lysates. Of note,
MYC-PLK1 (WT) overexpression strongly enhanced MTOR
and RPTOR signals in PLK1 IPs, whereas the LAMP2 signal
was strongly decreased (Fig. 2H). As endogenous MTOR and
RPTOR levels were unaltered in the lysates (Fig. 2H), our data
suggest that there is an increase in the amount of PLK1-
MTORC1 complexes upon MYC-PLK1 (WT) expression, and
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these complexes do not physically bind the lysosomal marker
LAMP2. Thus, our data are consistent with a model in which
active PLK1 dissociates MTORC1 from lysosomes. To test
whether its kinase activity is required for overexpressed PLK1
to detach MTORC1 from LAMP2, we transfected cells either
with MYC-PLK1 (WT), or with a dominant-negative lysine 82
to arginine mutated PLK1 variant (MYC-PLK1K82R),59 and per-
formed PLK1 IPs (Fig. 2I). Endogenous MTOR, RPTOR, and
LAMP2 levels were similar in lysates from MYC-PLK1 (WT)
or MYC-PLK1K82R transfected cells. In PLK1 IPs, the amounts
of coimmunoprecipitated MTOR and RPTOR were similar for
overexpression of MYC-PLK1 (WT) or dominant-negative
MYC-PLK1K82R. In contrast, LAMP2 signals were stronger in
PLK1 IPs from cells overexpressing dominant negative MYC-
PLK1K82R, as compared with MYC-PLK1 (WT)(Fig. 2I). This
suggests that inactive MYC-PLK1K82R binds MTORC1 and the
Figure 2. (For ﬁgure legend, see next page.)
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lysosomal protein LAMP2. Active MYC-PLK1 (WT) loses
LAMP2 association while it binds MTORC1 with the same efﬁ-
ciency as inactive MYC-PLK1K82R (Fig. 2I). In summary, these
data are consistent with the notion that PLK1 binds MTORC1
at lysosomes, and that active PLK1 dissociates the PLK1-
MTORC1 complex from the lysosomes, thereby mediating
MTORC1 inhibition. If this was the case, a decrease in
MTORC1 activity would be expected following overexpression
of wild type PLK1 as compared with inactive PLK1. To test
this, we analyzed RPS6KB (p70) T389 phosphorylation in
starved or amino acid- and insulin-stimulated cells that were
transfected with MYC-PLK1 (WT) or inactive MYC-PLK1K82R
(Fig. 2J). Consistent with an inhibitory function of active PLK1
toward MTORC1, RPS6KB (p70) phospho-(T389) induction
by amino acids plus insulin was lower in MYC-PLK1 (WT)-
transfected cells compared with MYC-PLK1K82R transfected
cells. Thus, we conclude that active MYC-PLK1 (WT) reduces
lysosomal association of the PLK1-MTORC1 complex, which
correlates with decreased RPS6KB (p70) T389 phosphorylation.
This indicates that decreased lysosomal association contributes
to MTORC1 inhibition by PLK1.
PLK1 inhibition reduces autophagy in an MTORC1-
dependent manner in interphase cells
As amino acid starvation is a condition that inhibits MTORC1
and increases autophagy, we used this condition to test if PLK1
inhibition activates MTORC1 and thereby inhibits autophagy.
We ﬁrst analyzed whether PLK1 contributes to MTORC1 inhi-
bition upon amino acid starvation. To this end, HeLa cells were
starved for amino acids, with or without PLK1 inhibition by
short-term (30 min) BI2536 treatment. The cells were har-
vested at 5 to 30 min after onset of amino acid starvation
(Fig. 3A). Consistent with MTORC1 inhibition, RPS6KB (p70)
phospho-(T389) declined over time and was fully inhibited at
30 min after onset of amino acid starvation. Notably, RPS6KB
(p70) T389 phosphorylation remained higher when PLK1 was
inhibited by BI2536, as compared with the control cells
(Fig. 3A, B). As the inhibitory effect of PLK1 toward MTORC1
is restricted to interphase cells, we analyzed phosphorylation of
the mitotic marker H3F3 at S10 in amino acid-starved and
BI2536-treated cells (Fig. S2A). H3F3 phosphorylation was
high in mitotic control cells but not detectable in amino acid-
starved and BI2536-treated cells, suggesting that these cultures
were nonsynchronized. Thus, PLK1 inhibition led to RPS6KB
(p70) T389 hyperphosphorylation in amino acid-starved inter-
phase cells. This suggests that PLK1 restricts MTORC1 activity
not only upon amino acid and insulin stimulation (Fig. 1B),
but also contributes to MTORC1 inhibition in response to
amino acid starvation (Fig. 3A, B).
As our data suggested that PLK1 inhibits MTORC1 by
reducing its lysosomal binding (Fig. 2H, I), we next tested if
PLK1 inhibition altered MTOR colocalization with the lyso-
somal marker LAMP2 in amino acid-starved cells. Indeed, IF
analysis showed that PLK1 inhibition by BI2536 signiﬁcantly
increased MTOR and LAMP2 colocalization (Fig. 3C) as tested
by the Pearson correlation coefﬁcient (r MTOR and LAMP2, control
D 0.33, SEM D 0.02; r MTOR and LAMP2, BI2536 D 0.47, SEM D
0.04; P MTOR and LAMP2, control, BI2536 D 0.006. A nonparametric
2-tailed Student t test was applied.) (Fig. 3D). Localization of
RRAGC/RAGC (Ras related GTP binding C), a known media-
tor of lysosomal MTOR localization,14 was not altered by
BI2536 treatment (Fig. 3E,F; r RRAGC and LAMP2, control D 0.53,
SEM D 0.06; r RRAGC and LAMP2, BI2536 D 0.49, SEM D 0.04; P
RRAGC and LAMP2, control, BI2536 D 0.72). This is in agreement with
earlier reports that RRAGC localization remains unaltered
upon changes in extracellular amino acid concentrations.14
Thus, PLK1 inhibition aberrantly enhanced MTOR colocaliza-
tion with LAMP2 in amino acid-starved cells, suggesting that
PLK1 inhibits MTORC1 by decreasing its association with
RRAGC-positive lysosomes.
As our earlier data indicated that MYC-PLK1 (WT) overex-
pression inhibits MTORC1 (Fig. 2I to J), and the extent of
interaction between them may contribute to PLK1-mediated
MTORC1 inhibition, we next tested whether endogenous
PLK1-MTORC1 binding was altered by amino acid starvation.
Therefore, we performed PLK1 IPs from amino acid-starved or
full medium-cultivated cells. We found that the signals for both
MTOR (Fig. 3G, H) and RPTOR (Fig. 3I, J) were increased in
PLK1 IPs from amino acid-starved cells. We consistently
immunoprecipitated less PLK1 from amino acid-starved cells,
which led to a decrease in PLK1 signals (Fig. 3G, I). Neverthe-
less, the signals for coimmunoprecipitated MTOR and RPTOR
were stronger for PLK1 IPs from amino acid-starved cells as
Figure 2. (see previous page) PLK1 resides with MTORC1 at lysosomes, and overexpression of active PLK1 decreases lysosomal association of the PLK1-MTORC1 complex.
(A) Immunoﬂuorescence analysis of HeLa cells that were cultured in full medium and stained with LAMP2 and MTOR antibodies. White regions in merged image (right)
of LAMP2 (green) and MTOR (magenta) indicate colocalization. Nuclei were stained with Hoechst 33342. Scale bar 20 mm. Representative images are shown for n D 3
independent experiments. (B) Immunoﬂuorescence analysis of HeLa cells that were cultured in full medium and stained with PLK1 and MTOR antibodies. White regions
in merged image (right) of PLK1 (green) and MTOR (magenta) indicate colocalization. Nuclei were stained with Hoechst 33342. Scale bar 20 mm. Representative images
are shown for n D 3 independent experiments. (C) Immunoﬂuorescence analysis of HeLa cells that were synchronized in prometaphase with nocodazole for 16 h and
released for 30 min in full medium. Cells were stained with PLK1 antibody. Nuclei were stained with Hoechst 33342. Scale bar: 10 mm. Representative images of cells in
metaphase (left) and anaphase (right) are shown for n D 3 independent experiments. (D) Analysis of input sample taken before fractionation in sucrose gradient (E). The
mitotic cell lysate was collected from HeLa shPLK1 knockdown cultures without mitotic shake-off. Samples were analyzed by immunoblotting. Data shown are representa-
tive of n D 2 independent experiments. (E) HeLa cells were starved for 1 h for amino acids and growth factors and stimulated with amino acids and insulin for 35 min.
Samples were separated in a 10 to 40% sucrose gradient and analyzed by immunoblotting. Data shown are representative of n D 3 independent experiments. (F) Quanti-
ﬁcation of data shown in (E) for nD 3 independent experiments. The percentage of PLK1 in either the lysosomal or the nuclear fraction is displayed. Data are represented
as mean § SEM. (G) HeLa cells were cultured in full medium. Immunoprecipitation (IP) was performed with PLK1 and control (mock) antibodies. Samples were analyzed
by immunoblotting. Data shown are representative of n D 3 independent experiments. (H) HeLa cells overexpressing wild type MYC-PLK1 (WT) or empty vector were cul-
tured in full medium. Immunoprecipitation (IP) was performed with PLK1 and control (mock) antibodies. Samples were analyzed by immunoblotting. Data shown are rep-
resentative of n D 3 independent experiments. (I) HeLa cells overexpressing MYC-PLK1 (WT) or kinase-defective, dominant negative MYC-PLK1K82R were cultured in full
medium. Immunoprecipitation (IP) was performed with PLK1 and control (mock) antibodies. Samples were analyzed by immunoblotting. Data shown are representative
of n D 3 independent experiments. (J) HeLa cells overexpressing MYC-PLK1 (WT) or kinase-defective, dominant negative MYC-PLK1K82R were starved for 1 h for amino
acids and growth factors, and stimulated with amino acids and insulin for 35 min. Cells were then starved for amino acids for 10 min as indicated, and samples were ana-
lyzed by immunoblotting. Data shown are representative of nD 3 independent experiments.
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compared with full medium-cultivated cells (Fig. 3G, I), indi-
cating an increase in PLK1-MTOR and -RPTOR binding under
amino acid starvation. To quantify the relative amount of
RPTOR or MTOR bound to PLK1 in nonstarved versus amino
acid-starved cells, we normalized the RPTOR and MTOR sig-
nals to the PLK1 levels in each respective IP. We found that
physical PLK1 interaction with RPTOR and MTOR
signiﬁcantly increased upon amino acid withdrawal (Fig. 3H,
J). We conclude that increased MTORC1-PLK1 binding occurs
when MTORC1 is inhibited by amino acid starvation. This is
consistent with our earlier ﬁnding that overexpression of active
PLK1 led to increased PLK1-MTORC1 binding and reduced
lysosomal association of the PLK1-MTORC1 complex, corre-
lating with reduced MTORC1 activity (Fig. 2H to J). As amino
Figure 3. (For ﬁgure legend, see next page.)
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acid deprivation inhibits MTORC1, we tested if MTOR inhibi-
tion by Torin1 could phenocopy the observed increase in
PLK1-MTOR binding in amino acid-starved cells (Fig. 4A, B).
Therefore, we performed MTOR IPs from HeLa cells cultivated
in full medium and treated for 30 min with Torin1 or carrier
(Fig. 4A, B). Torin1 inhibited RPS6KB (p70) T389 phosphory-
lation but did not alter PLK1-MTOR binding, suggesting that
MTORC1 kinase activity does not control its own binding to
PLK1. Next we tested if PLK1 activity affected the induction of
PLK1-MTOR binding by amino acid starvation. Therefore, we
performed PLK1 IPs from HeLa cells that were treated with the
PLK1 inhibitor BI2536 or carrier, and starved for amino acids
or cultivated in full medium. Amino acid withdrawal enhanced
endogenous PLK1-MTOR binding 4-fold to the same extent in
the presence or absence of BI2536 (Fig. 4C, D), suggesting that
PLK1 kinase activity does not mediate enhanced PLK1-MTOR
binding upon amino acid deprivation. Thus, amino acid depri-
vation may represent an input that is separate from MTORC1
and PLK1, as inhibition of MTOR or PLK1 did not alter
increased PLK1-MTOR binding in amino acid-starved cells. Of
note, we observed that acute amino acid starvation not only sig-
niﬁcantly enhanced PLK1-MTOR binding (Fig. 4E, F) but also
cytoplasmic colocalization of PLK1 and MTOR (Fig. 4G, H).
This suggests that enhanced PLK1-MTOR association in amino
acid-deprived cells may contribute to MTORC1 inhibition, via
PLK1-mediated MTORC1 localization away from lysosomes.
As MTORC1 inhibition derepresses autophagy,10 we next
tested if PLK1 via MTORC1 inhibition enhances autophagy.
To this end, we inhibited PLK1 by BI2536 in amino acid-
starved and control cells and detected MAP1LC3A/LC3
(microtubule-associated protein 1 light chain 3 a)35 which is a
widely used autophagy marker.35,60 Unprocessed LC3 (LC3-I)
is soluble and resides in the cytoplasm. Upon autophagy induc-
tion, LC3-I is processed at its C terminus and conjugated to
phoshatidylethanolamine (referred to as LC3-II). LC3-II associ-
ates with autophagosomal inner and outer membranes,60 and
becomes degraded upon fusion with lysosomes.28,30 Yet, dual
processing of LC3 renders the interpretation of LC3-II signals
challenging.35 On the one hand, LC3 is lipidated and integrated
into the phagophore membrane (the precursor to the autopha-
gosome), leading to an increase in LC3-II signal in
immunoblots. On the other hand, LC3-II is degraded by lyso-
somal proteases upon autophagosomal-lysosomal fusion,
decreasing the LC3-II signal. Thus, LC3-II degradation can
mask the increase in LC3-II upon autophagy induction. To pre-
vent LC3-II degradation and enable detection of LC3-II accu-
mulation, we supplemented all media for autophagy assays
with the v-ATPase inhibitor baﬁlomycin A1 (BafA). BafA
inhibits autophagosomal-lysosomal fusion, a late step in the
autophagy process. Thus, LC3-II can still be integrated into the
phagophore membrane, but it is no longer degraded by lyso-
somal proteases, and LC3-II accumulation can be reliably
detected. In keeping with this, BafA strongly induced LC3-II
levels in HeLa cells (Fig. S2D).
Upon amino acid starvation for 30 min, we observed that
PLK1 inhibition by BI2536 caused a signiﬁcant decrease in
LC3-II levels (Fig. 5A, B), indicating that PLK1 plays a positive
role in autophagy. Next, we tested whether LC3-II reduction by
PLK1 inhibition required MTOR activity. To this end, we com-
bined PLK1 inhibition by BI2536 with MTOR inhibition by
Torin1, and starved cells for amino acids (Fig. 5C, D). Whereas
PLK1 inhibition by BI2536 signiﬁcantly reduced LC3-II levels,
BI2536 had no signiﬁcant effect on LC3-II levels when com-
bined with the MTOR inhibitor Torin1 (Fig. 5C, D). We also
analyzed LC3-II levels in shControl and shPLK1 knockdown
cells, without and with Torin1 treatment. In these experiments,
mitotic cells were removed by shake off. PLK1 knockdown sig-
niﬁcantly reduced LC3-II, and this effect was suppressed by
Torin1 treatment (Fig. 5E, F). Thus, LC3-II reduction by PLK1
inhibition or knockdown required MTOR activity, suggesting
that PLK1 positively contributes to autophagy by inhibiting
MTORC1.
To further validate a role for PLK1 in autophagy regulation, we
used a tandem mRFP-GFP-LC3 reporter,35,60,61 which is a stan-
dard tool to monitor the status of the autophagy process. GFP
(green ﬂuorescent protein) displays higher sensitivity to low pH
than mRFP61 (monomeric red ﬂuorescent protein). Therefore,
the tandemmRFP-GFP-LC3 reporter allows tracking of acidiﬁca-
tion of autolysosomes by providing a readout for autophagosome
and autolysosome numbers.35,60,61 HeLa cells were transiently
transfected with the reporter construct in combination with PLK1
or control siRNA knockdown, and subjected to full-medium
Figure 3. (see previous page) PLK1 inhibition hyperactivates MTORC1 and increases lysosomal MTORC1 localization in amino acid-starved interphase cells. (A) HeLa cells
were starved for 1 h for amino acids and growth factors, and stimulated with amino acids and insulin for 35 min. Cells were then starved for amino acids for 5, 10, 15 and
30 min and treated with BI2536 or carrier, as indicated. Samples were analyzed by immunoblotting. Data shown are representative of n D 4 independent experiments.
(B) Quantiﬁcation of data shown in (A). Ratio of RPS6KB (p70) phospho-(T389):RPS6KB (p70) was calculated for n D 4 (5 min starvation and 15 min starvation); n D 3
(10 min starvation) independent experiments. Data are normalized to 1 for starvation control condition and represented as mean § SEM. A nonparametric 2-tailed Stu-
dent t test was applied; , P  0.05. (C) Immunoﬂuorescence analysis of HeLa cells that were starved for 1 h for amino acids and growth factors, stimulated with amino
acids and insulin for 35 min, followed by 30 min amino acid starvation, without or with the PLK1 inhibitor BI2536. Staining was performed with MTOR and LAMP2 anti-
bodies. White regions in merged image (right) of MTOR (green) and LAMP2 (magenta) indicate colocalization. Nuclei were stained with Hoechst 33342. Scale bar 20 mm.
Representative images are shown for n D 3 independent experiments. (D) Analysis of MTOR-LAMP2 colocalization by the Pearson correlation coefﬁcient for experiment
shown in (C). Data are represented as mean § SEM, and are representative of n D 3 independent experiments. A nonparametric 2-tailed Student t test was applied; , P
 0.05. (E) Immunoﬂuorescence analysis of HeLa cells that were treated as described in (C). Staining was performed with RRAGC and LAMP2 antibodies. White regions in
merged image (right) of RRAGC (green) and LAMP2 (magenta) indicate colocalization. Nuclei were stained with Hoechst 33342. Scale bar 20 mm. Representative images
are shown for n D 3 independent experiments. (F) Analysis of RRAGC-LAMP2 colocalization by the Pearson correlation coefﬁcient for experiment shown in (E). Data are
represented as mean § SEM, and are representative of n D 3 independent experiments. A nonparametric 2-tailed Student t test was applied; ns, nonsigniﬁcant. (G) HeLa
cells were either cultured in full medium or starved for amino acids and growth factors for 16 h. Immunoprecipitation (IP) was performed with PLK1 and control (mock)
antibodies. Samples were analyzed by immunoblotting. Data shown are representative of n D 3 independent experiments. (H) Quantiﬁcation of IP samples shown in (G).
Ratio of MTOR:PLK1 was calculated for nD 3 independent experiments. Data are normalized to 1 for control condition and represented as mean § SEM. A nonparametric
2-tailed Student t test was applied; , P  0.05. (I) HeLa cells were treated as described in (G). IP was performed with PLK1 and control (mock) antibodies. Samples were
analyzed by immunoblotting. Data shown are representative of n D 4 independent experiments. (J) Quantiﬁcation of IP samples shown in (I). Ratio of RPTOR:PLK1 was
calculated for n D 4 independent experiments. Data are normalized to 1 for control condition and represented as mean § SEM. A nonparametric 2-tailed Student t test
was applied; , P  0.05.
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conditions or amino acid starvation. Mitotic cells were removed
by shake-off. Fixed cells were stained with Hoechst, imaged by
wide-ﬁeld microscopy (Fig. 6A), and deconvoluted images were
analyzed as described previously.62 The few remaining mitotic
cells, as determined by chromatin condensation state detected by
Hoechst DNA staining, were omitted from the analysis. GFP
puncta, representing autophagosomes, and mRFP puncta, repre-
senting autolysosomes plus autophagosomes, were counted. To
Figure 4. Starvation enhances PLK1-MTOR binding and cytoplasmic PLK1-MTOR colocalization. (A) HeLa cells were cultured in full medium and treated for 30 min with Torin1
or carrier, respectively. Immunoprecipitation (IP) was performed with PLK1 and control (mock) antibodies. Samples were analyzed by immunoblotting. Data shown are represen-
tative of n D 3 independent experiments. (B) Quantiﬁcation of IP samples shown in (A). Ratio of MTOR:PLK1 was calculated for n D 3 independent experiments. Data are nor-
malized to 1 for full medium condition and represented as mean § SEM. A nonparametric 2-tailed Student t test was applied; ns, nonsigniﬁcant. (C) HeLa cells were either
cultured in full medium or starved for amino acids and growth factors for 16 h. Cells were then treated with BI2536 or carrier, as indicated. Immunoprecipitation (IP) was per-
formed with PLK1 and control (mock) antibodies. Samples were analyzed by immunoblotting. Data shown are representative of n D 3 independent experiments. (D) Quantiﬁca-
tion of data shown in (C). Fold change of MTOR:PLK1 ratio in starved versus control cells was calculated across n D 3 independent experiments, for carrier or BI2536 treated
cells, as indicated. Data are normalized to lane 1 (C), and represented as mean § SEM. A nonparametric 2-tailed Student t test was applied; ns, nonsigniﬁcant. (E) HeLa cells
were starved for 1 h for amino acids and growth factors, and stimulated with amino acids and insulin for 35 min. Afterwards, for starvation, amino acids were withdrawn for
30 min. Immunoprecipitation (IP) was performed with PLK1 and control (mock) antibodies. Samples were analyzed by immunoblotting. Data shown are representative of n D 3
independent experiments. (F) Quantiﬁcation of data shown in (E). Ratio of MTOR:PLK1 was calculated for n D 3 independent experiments. Data are normalized to 1 for amino
acids and insulin condition, and represented as mean § SEM. A nonparametric 2-tailed Student t test was applied; , P  0.001. (G) Immunoﬂuorescence analysis of HeLa cells
that were starved for 1 h for amino acids and growth factors, stimulated with amino acids and insulin for 35 min, followed by 30 min of amino acid starvation, as indicated.
Staining was performed with PLK1 and MTOR antibodies. White regions in merged image (right) of PLK1 (green) and MTOR (magenta) staining indicate colocalization; insert 1
shows a region with lysosomal MTOR pattern; insert 2 shows a cytoplasmic region without lysosomal MTOR pattern. Nuclei were stained with Hoechst 33342. Scale bar:
20 mm. Representative images are shown for n D 3 independent experiments. (H) Analysis of PLK1-MTOR colocalization by the Pearson correlation coefﬁcient for experiment
shown in (G). Ten representative cells were quantiﬁed for each condition. Data are represented as mean § SEM and are representative of n D 3 independent experiments. A
nonparametric 2-tailed Student t test was applied; , P  0.05. (E, F, G, H) aa, amino acids; ins, insulin.
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determine the percentage of autolysosomes, we subsequently cal-
culated the difference between mRFP and GFP puncta, which we
expressed as the percentage of all mRFP positive puncta per cell
(Fig. 6B). As expected, starvation increased the percentage of
autolysosomes consistent with enhanced autophagy. PLK1
knockdown reduced the percentage of autolysosomes under full
medium conditions and upon amino acid starvation (Fig. 6B).
This is in agreement with the decline in LC3-II levels upon PLK1
inhibition detected by immunoblotting (Fig. 5A to F).
We further consolidated this ﬁnding by analyzing the auto-
phagy substrate SQSTM1/p62 (sequestosome 1). SQSTM1 is
recruited by LC3 into autophagosomes, and thus SQSTM1
punctate structures represent LC3-positive autophagosome-
associating SQSTM1. When autophagy is blocked, SQSTM1
foci accumulate due to inefﬁcient autophagosome turnover.35
We detected SQSTM1 foci by IF in amino acid-starved cells
that were treated with the PLK1 inhibitor BI2536 or carrier
(Fig. 6C, D). In agreement with the reduced LC3-II levels
(Fig. 5A to F) and decreased percentage of autolysosomes
(Fig. 6B), we found that SQSTM1 foci numbers were signiﬁ-
cantly increased in PLK1 inhibited cells, compared with the
control cells, thus providing further evidence that PLK1 is a
positive regulator of autophagy.
The autophagy analyses reported above were performed in
interphase cells. However, we could not rule out that PLK1
may regulate autophagy in mitotic cells as well. To test this,
we analyzed LC3-II during mitosis. We arrested cells in
mitosis by a consecutive aphidicolin-nocodazole block,
released them for different times as indicated (Fig. S2E), and
detected cell cycle markers and LC3-II by immunoblotting.
Consistent with an increased amount of mitotic cells in the
culture, we observed increased phosphorylation of H3F3 at
Figure 5. PLK1 inhibition reduces the autophagy marker LC3-II in interphase cells. (A) HeLa cells were starved for 1 h for amino acids and growth factors, stimulated with
amino acids and insulin for 35 min, followed by 30 min amino acid starvation. All media were supplemented with baﬁlomycin A1. BI2536 was added as indicated for
30 min. Data shown are representative of n D 3 independent experiments. (B) Quantiﬁcation of data shown in (A). Ratio of LC3-II:GAPDH was calculated for n D 3 inde-
pendent experiments. Data are normalized to 1 for the control condition and represented as mean § SEM. A nonparametric 2-tailed Student t test was applied; , P 
0.05. (C) HeLa cells were treated with BI2536 and/or Torin1 as indicated, and stimulated as described in (A). Samples were analyzed by immunoblotting. Data shown are
representative of n D 3 independent experiments. (D) Quantiﬁcation of data shown in (C). Ratio of LC3-II:GAPDH was calculated for n D 3 independent experiments.
Data are normalized to 1 for the control condition (no Torin1, no BI2536) and represented as mean § SEM. A nonparametric 2-tailed Student t test was applied; ns, non-
signiﬁcant; , P  0.05. (E) PLK1 (shPLK1) or control (shControl) shRNA HeLa cells were starved for 1 h for amino acids and growth factors, stimulated with amino acids
and insulin for 35 min, followed by 20 min amino acid starvation. All media were supplemented with baﬁlomycin A1. Cells were treated with Torin1 as indicated. Mitotic
cells were removed by shake-off. Hence, only interphase cells were analyzed. Data shown are representative of n D 4 independent experiments. (F) Quantiﬁcation of data
shown in (E). Ratio of LC3-II:GAPDH was calculated for n D 4 independent experiments. Data are normalized to 1 for the shControl condition (no Torin1) and represented
as mean § SEM. A nonparametric 2-tailed Student t test was applied; ns, nonsigniﬁcant; , P  0.05.
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serine 10 and decreased levels of the G1/S phase marker
CCNE1. Autophagy, as monitored by LC3-II levels, was low
in mitotic cells as compared with control cells from an asyn-
chronous culture (Fig. S2E), which is consistent with previ-
ous reports.36,37 Thus, we conclude that mitotic cells display
low autophagy, suggesting that PLK1 may promote auto-
phagy primarily in nonmitotic cells. This is also in agree-
ment with our ﬁnding that autophagic control by PLK1
depends on MTOR activity (Fig. 5C to F), which is inhibited
during mitosis (Fig. 1F).
Figure 6. (For ﬁgure legend, see next page.)
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We next aimed to determine whether PLK1s role in autophagy
in nonmitotic cells is conserved from invertebrates to mammals.
For this purpose, we used the genetic model organism C. elegans.
We analyzed the role of plk-1, the C. elegans PLK1 ortholog, in
dauer larvae, a developmentally arrested stage of C. elegans in
which the animals display cell cycle quiescence and therefore con-
sist of nonmitotic cells. Dauer entry and G1 cell cycle arrest in
C. elegans larvae occur in response to environmental stresses,
including starvation.63 Speciﬁcally, we used animals carrying a
thermosensitive, mutant allele for the INSR-IGF1R homolog
DAF-2, daf-2(e1370), and stably expressing the transgene
GFP::LGG-164 (orthologous to mammalian LC3; scheme of the
experimental setup provided in Fig. S2F). daf-2(e1370) mutants
enter the dauer stage upon shift to the restrictive temperature
(25C), during which markers of autophagy are increased.65
Moreover, RNAi knockdown of genes involved in the autophagic
process changes the subcellular localization of GFP::LGG-1 in
hypodermal cells of daf-2(e1370) mutants, while causing an
enhanced GFP::LGG-1 signal in these cells.65 Consistent with
these observations, we found a 3-fold increase in GFP::LGG-1
intensity in the body of daf-2(e1370) dauers subjected to RNAi-
mediated inhibition of the autophagy WIPI protein atg-18,66
compared with control RNAi (Fig. 6E, F). This indicates that inhi-
bition of autophagy causes increased GFP::LGG-1 levels in daf-2
dauer larvae. When we quantiﬁed GFP::LGG-1 intensity in daf-2
dauers subjected to plk-1 RNAi, we observed that inhibition of
plk-1, like inhibition of atg-18, signiﬁcantly increased GFP::LGG-
1 levels compared with dauers subjected to control RNAi (Fig. 6E,
F). Thus, plk-1 RNAi, similar to inhibition of PLK1 in mamma-
lian cells, appeared to cause a block of autophagy, suggesting that
PLK1/PLK-1 is a conserved regulator of autophagy. As C. elegans
dauer larvae consist of G1/S interphase cells,
63 our data further
suggest that, similarly to mammalian cells, C. elegans PLK-1 posi-
tively regulates autophagy in nonmitotic cells.
Discussion
In the present study, we show that PLK1 physically binds and
phosphorylates MTORC1. In interphase cells, inhibition of
PLK1 increases MTORC1 activity, as measured by RPS6KB
(p70) phosphorylation at T389. Consistently, MTORC10s lyso-
somal association (Fig. 2I) and activity (Fig. 2J) are decreased
in cells overexpressing active PLK1, as compared with the inac-
tive protein. In line with this, PLK1 inhibition mitigates auto-
phagy in an MTOR-dependent manner (Fig. 5C to F). Positive
regulation of autophagy by PLK1/PLK-1 occurs in C. elegans
and mammalian cells, suggesting that this PLK1 function is
evolutionary conserved.
PLK1 is mainly perceived as a regulator of mitotic progres-
sion.2,3 Here we describe a novel function of PLK1 in inter-
phase cells where it inhibits MTORC1 and activates autophagy
under nutrient sufﬁciency and amino acid deprivation. Our
data suggest that the functions of PLK1 in mitotic and inter-
phase cells are mediated by distinct mechanisms since (i) PLK1
inhibition increases MTORC1 activity in interphase cells
(Fig. 1G, H) but not in mitotic cells (Fig. 1D, E); (ii) PLK1 inhi-
bition reduces autophagy in interphase cells (Figs. 5 and 6). In
contrast, mitotic cells display high PLK1 levels46,47 (Fig. 1F) but
low autophagy (Fig. S2E), suggesting that PLK1 promotes auto-
phagy primarily in nonmitotic cells; (iii) autophagy inhibition
by PLK1 inhibition depends on MTOR activity (Fig. 5C to F).
MTORC1 in mitotic cells is inhibited (Fig. 1F) and cannot be
activated by PLK1 inhibition (Fig. 1D, E). Thus, we conclude
that PLK1 inhibits MTORC1 and activates autophagy in inter-
phase but not in mitotic cells. Which mechanisms may coordi-
nate PLK1’s mitotic and interphase functions is currently
unknown and will require further investigation.
Our ﬁnding that PLK1 inhibits MTORC1 in interphase but
not in mitotic cells helps to resolve seemingly contradictory
reports on the effects of PLK1 inhibition on MTORC1. For
example, our ﬁndings are in agreement with Sparta et al.26 who
report that the PLK1 inhibitor BI6727 increases RPS6KB (p70)
and RPS6 phosphorylation. Yet, this has been so far debatable
as 4 other studies22-25 reported that PLK1 inhibition suppresses
the phosphorylation of MTORC1 substrates. At ﬁrst glance this
seems to be at odds with our ﬁndings and those of Sparta
et al.26 However, Renner et al.22 Astrinidis et al.,23 Zhang
et al.24 and Li et al.25 use long-term treatments with PLK1
inhibitors or siRNA, increasing the amounts of mitotic cells in
the cultures. In some studies, long-term PLK1 inhibition is
even combined with a mitotic block.22,23 Thus, the reduced
MTORC1 activity reported in those studies is measured in
mitotic cells. In agreement with those data, we also show that
MTORC1 is inhibited in mitotic cells (Fig. 1F). However, after
removal of mitotic cells, our data reveal that PLK1 inhibition
activates MTORC1 in interphase cells (Fig. 1G), which corre-
sponds with data from Sparta et al.26 Thus, our ﬁndings resolve
and unify earlier—seemingly paradoxical—ﬁndings on PLK1
inhibitor effects on the MTORC1 substrate RPS6KB (p70).
Our results also complement previous studies on PLK1 inhib-
itor effects on autophagy. We observed here that PLK1 inhibition
causes a decline in autophagy in interphase cells, as determined
Figure 6. (see previous page) PLK1 inhibition impairs autophagy in nonmitotic cells and in C. elegans dauers. (A) HeLa cells were transfected with mRFP-GFP-LC3 tandem
reporter, followed by PLK1 siRNA transfection on the next day. Cells were either kept in full medium, or starved for serum and amino acids for 16 h. Mitotic cells were
removed by shake-off before ﬁxation of cells 24 h after siRNA transfection. Representative images are shown for each condition. Scale bar 10 mm. Data shown are repre-
sentative of n D 2 independent experiments. (B) Quantiﬁcation of experiment shown in (A). The numbers of green puncta (autophagosomes) and red puncta (autolyso-
somes plus autophagosomes) were counted for nonmitotic cells. Data shown are represented as mean § SEM for n D 30 cells for control knockdown, full medium, n D
43 cells for siPLK1, full medium, n D 35 cells for control knockdown, starvation condition, and n D 26 for siPLK1 starvation condition. A nonparametric 2-tailed Student t
test was applied; , P  0.05; , P  0.001. (C) Immunoﬂuorescence analysis of HeLa cells that were starved for 1 h for amino acids and growth factors, stimulated with
amino acids and insulin for 35 min, followed by 30 min amino acid starvation. All media were supplemented with baﬁlomycin A1. Staining was performed with SQSTM1
antibody and Hoechst 33342. Shown are maximum intensity projections. Scale bar 20 mm. Representative images are shown for n D 3 independent experiments. (D)
Quantiﬁcation of experiment shown in (C). The total area of SQSTM1-positive foci was calculated and normalized to the number of nuclei. n D 126 cells for control condi-
tion and n D 105 cells for BI2536 treated condition. Data are represented as mean § SEM, and are representative of n D 3 independent experiments. A nonparametric 2-
tailed Student t test was applied; , P  0.05. (E& F) daf-2(e1370) animals expressing GFP::LGG-1 were fed bacteria expressing control, atg-18 or plk-1 dsRNA from hatch-
ing, and raised at the nonpermissible temperature (25C) to induce dauers. (E) Micrographs of »8 to 10 dauer animals lined up next to each other were taken 6 d after
the temperature shift. Scale bar 200 mm. (F) GFP::LGG-1 ﬂuorescence (mean § s.d. of »8–10 animals, P<0.0001, one-way ANOVA) was quantiﬁed. Data shown are rep-
resentative of 3 independent experiments.
498 S. RUF ET AL.
by the reduction in LC3-II accumulation and autolysosome
numbers (Fig. 5, Fig. 6A, 6B). In agreement, Valianou et al.39
show in TSC1- or TSC2-deﬁcient lymphangioleiomyomatosis
patient derived cells that BI2536 moderately inhibits autophagy.
Our ﬁnding that PLK1 regulates MTORC1 adds to the interpre-
tation of these data. As loss of TSC1 or TSC2 leads to massive
MTORC1 hyperactivation, MTORC1 can most probably not be
much further activated by PLK1 inhibition in a TSC1- or TSC2-
deﬁcient background. This may explain the only moderate effect
of BI2536 on autophagy observed in that study. Another study
in LNCaP cells reports that long-term treatment with BI2536 for
5 d leads to mitotic arrest and necroptosis, correlating with cell
death related autophagy activation.40 In our hands, autophagy
was decreased in HeLa cells upon a 38 h mitotic block
(Fig. S2E). Thus, autophagic activity during mitosis may vary
depending on the length of cell cycle arrest and the cell type
studied.
We ﬁnd here that the MTORC1 component RPTOR is
directly phosphorylated in vitro by PLK1. Which RPTOR resi-
dues may be PLK1 substrate sites? We analyzed the RPTOR
sequence for known consensus phosphorylation motifs of
PLK1,67 but did not ﬁnd any. Thus, PLK1 substrate sites in
RPTOR cannot be theoretically predicted. Three RPTOR phos-
phorylation sites at S722, S863, and S877 have been previously
identiﬁed by 2 studies,68,69 which report on PLK1-dependent
mitotic phosphoproteomes. We did not observe changes in
phosphorylation of RPTOR at S722 and S863 upon BI2536
treatment in nonmitotic cells (Fig. S2G). For RPTOR phospho-
(S877), we did not detect a speciﬁc signal with the available
antibody (data not shown). Also other reported RPTOR phos-
phorylation sites70 at S859 and T706 remained unchanged by
BI2536 (Fig. S2G). Thus, further studies are needed to gain
insight into RPTOR residues that are phosphorylated by PLK1
in interphase cells. Likewise, discovery proteomic studies are
required to identify other interphase substrates and thereby
more generally delineate the interphase response of the PLK1
phosphoproteome to changes in nutrient supply.
The central platform for MTORC1 signaling is the lysosome,
which is also the essential compartment for autophagy. Consis-
tent with a role for PLK1 in MTORC1 regulation and auto-
phagy, we report that PLK1 colocalizes with MTOR in a
lysosomal pattern (Fig. 2A, B) and the lysosomal marker
LAMP2 coimmunoprecipitates with PLK1 (Fig. 2G). Further-
more, in sucrose gradients PLK1 is detected in the lysosomal
fraction, jointly with MTOR and RPTOR, and the MTORC1
regulator TSC2 (Fig. 2E, F). This ﬁnding is intriguing as there
is so far no other report on lysosomal targeting of PLK1. Con-
sistent with PLK1s lysosomal association reported here, PLK1
contains a GY motif which is a lysosomal targeting signal.71
Under which physiological conditions and in response to
which stimuli does PLK1 inhibit MTORC1? We ﬁnd here that
PLK1 inhibition increases MTORC1 activity both under nutri-
ent sufﬁciency (Fig. 1B, C, G to J) and amino acid withdrawal
(Fig. 3A, B), and the extent of induction of RPS6KB (p70) T389
phosphorylation by PLK1 inhibition is equally strong in nutri-
ent-induced (Fig. 1C, H) and starved cells (Fig. 3B). This sug-
gests that PLK1 is active and inhibits MTORC1 in both
conditions. Of note, short- and long-term starvation enhances
binding of endogenous PLK1 with MTORC1 (Fig. 3G to J, 4E,
F), and this is independent of MTORC1 or PLK1 kinase activity
(Fig. 4A to D). This suggests that amino acid starvation regu-
lates upstream cues, which cause enhanced PLK1-MTOR asso-
ciation. The molecular mediators that control starvation-
induced PLK1-MTOR binding remain to be determined.
Whereas PLK1 kinase activity does not affect starvation-
induced PLK1-MTOR binding (Fig. 4C, D), PLK1 inhibition
does lead to aberrant lysosomal localization of the PLK1-
MTOR complex (Fig. 3C, D). This suggests that the increased
PLK1-MTOR interaction in response to amino acid starvation
does not happen at the lysosome, but another localization, e.g.,
in the cytoplasm. This is in agreement with the enhanced cyto-
plasmic colocalization of MTOR and PLK1 upon amino acid
starvation (Fig. 4G, H). This implies that enhanced PLK1-
MTOR binding in starved cells is a separate mechanism that
indirectly adds to PLK1s inhibitory effect on MTORC1 via
localization away from lysosomes (scheme on the 2 separate
mechanisms provided in Fig. S2H).
Similar to MTORC1 activity, its localization as well as
autophagy are altered by PLK1 inhibition both under nutri-
ent starvation and sufﬁciency. Increased lysosomal localiza-
tion or binding of MTOR upon PLK1 inactivation can be
detected in starved (Fig. 3C, D) and full medium cultivated
cells (Fig. 2I). Hence, PLK1 contributes under both condi-
tions to MTOR relocalization away from lysosomes. In
keeping with this, PLK1 inhibition mitigates autophagy
both under full medium conditions and in starved cells
(Fig. 6A, B). We conclude that MTORC1 inhibition by
PLK1 is a general mechanism, which is not restricted to
starved cells only, and consequently PLK1 positively con-
tributes to autophagy both under starvation and nutrient-
replete conditions (see scheme Fig. S2H). Of note, auto-
phagy does not only occur in starved cells, but is also a crit-
ical housekeeping and prosurvival pathway under nutrient
sufﬁciency. Basal autophagy maintains, for example, protein
homeostasis by removing misfolded proteins, and mobilizes
cellular energy and nutrient stores to maintain a stable pool
of metabolite intermediates (reviewed by Kaur et al29).
Our ﬁnding that PLK1, next to mitotic progression, pro-
motes autophagy in interphase cells suggests that for therapies
of low grade tumors, which typically contain only 5% to 10%
mitotic cells, PLK1 inhibitors may perform better than other
purely antimitotic agents. As novel therapeutics are often tested
ﬁrst in advanced tumors, this point may have been missed so
far, and clinical studies are needed to address performance of
PLK1 inhibitors vs other antimitotics such as paclitaxel in low
grade tumors. Beyond this, our ﬁndings suggest that combina-
torial targeting of MTORC1 and PLK1 may hold promise for
cancer treatment. PLK11,4,72 and MTOR8,9 are common drug
targets in cancer therapy, but combinatorial treatments are
rarely tested even in preclinical studies. It seems promising that
combination of the dual phosphoinositide 3-kinase-MTOR
inhibitor BEZ235 and the PLK1 inhibitor BI2536 in xenograft
models of colorectal cancer shows that either inhibitor alone
fails to enhance apoptosis, but combinatorial treatment inhibits
MTORC1 readouts and leads to massive tumor cell death.73
We show here that PLK1 inhibition can activate MTORC1 and
suppress autophagy. As this may affect tumor cell survival and
growth, we advocate cautious monitoring of MTORC1 and
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autophagy readouts in clinical trials with PLK1 inhibitors. Cor-
relation of such data with clinical outcome may allow develop-
ment of strategies for optimized (combinatorial) cancer
therapies, to simultaneously target PLK1 and MTOR in tumors
where MTORC1 is activated by PLK1 inhibition.
Materials and methods
Nomenclature
Genes and proteins are designated according to the recommen-
dations of the HUGO gene nomenclature committee (HGNC).
Cell culture and cell treatments
HeLa a Kyoto cells were cultivated in full medium Dulbec-
co’s modiﬁed Eagle’s medium (DMEM; PAN Biotech, P04–
03600) supplemented with 10% fetal calf serum (FCS; PAA,
A15–102, Lot A10208–0991), 3 mM L-glutamine (Gibco,
Life Technologies, 25030–024) at 37C, 7.5% CO2. For stim-
ulation with amino acids and insulin, cells were cultivated
in DMEM, supplemented with 3 mM L-glutamine and
100 nM insulin (Sigma-Aldrich, I1882), for the indicated
time points. Prior to starvation experiments, cells were
washed twice with phosphate-buffered saline (PBS; PAN
Biotech, P04–36500). Starvation was either performed for
amino acids and growth factors in Hank’s balanced salt
solution (HBSS; PAN Biotech, P04–32505), or for amino
acids in amino acid-free DMEM (PAN Biotech, P04–01507)
supplemented with 4.5 g/l glucose (Sigma-Aldrich, G7021)
and 100 nM insulin, as indicated. Mitotic shake-off was
performed where indicated to remove the mitotic cells.
Prior to the mitotic shake-off, cells were starved 16 h for
amino acids and growth factors in HBSS. Nocodazole or
consecutive aphidicolin-nocodazole treatment were per-
formed as described before.74 In brief, for consecutive aphi-
dicolin-nocodazole treatment cells were treated 16 h with
1.6 mg/mL aphidicolin (Sigma-Aldrich, A0781), followed by
a release into the cell cycle using full medium for 7 h and
subsequently treated with 100 ng/mL nocodazole (Sigma-
Aldrich, M1404) for 15 h, followed by release for the indi-
cated times.
siRNA knockdown of PLK1 was induced using ON-TAR-
GET plus SMARTpool siRNA, ﬁnal concentration 10 nM
(Dharmacon, L-003290–00). siRNA transfection was per-
formed using Lipofectamine 2000, (Life Technologies, 11668–
019) and DNA transfection was performed with JetPEI (Poly-
Plus, 101–40) according to the manufacturer’s protocol.
Overexpression of PLK1 was performed using the following
constructs: empty vector pRcCMV (Invitrogen V75020),
pRcCMV MYC-PLK1K82R (Addgene plasmid 41157, deposited
by Erich Nigg),59 and pRcCMV MYC-PLK1 (WT) (Addgene
plasmid 41160, deposited by Erich Nigg).38 The medium was
exchanged 6 h post transfection. Cells were harvested after
removal of the mitotic cells by mitotic shake-off 24 h or 48 h
post transfection, with similar results.
The shPLK1 HeLa cell line was generated using the pTRIPZ
system (Dharmacon). For virus generation HEK293T cells were
cotransfected using jetPEI with the PLK1 shRNA construct,
(target sequence shPLK1: CTGTCTGAAGCATCTTCTG;
Dharmacon, RHS4740-EG5347) or a nontargeting control
sequence, respectively, with the Trans-Lentiviral shRNA Pack-
aging system. The virus supernatant was harvested 72 h after
transfection. HeLa cells were seeded in the morning and the
infection with the virus supernatant was performed for 16 h.
The transduction step was repeated twice. Selection of success-
fully transduced cells was achieved by adding puromycin (ﬁnal
concentration 2 mg/mL; Sigma-Aldrich, P8833). A stably trans-
duced doxycycline-inducible HeLa shRPTOR cell line and a
control cell line (shControl) harboring a nontargeting control
sequence were described previously.45 Knockdown was induced
with doxycyline for 3 d (ﬁnal concentration 2 mg/mL; Sigma-
Aldrich, D3447). Doxycycline was removed for 16 h before the
start of all experiments in this study.
Antibodies and reagents
The following antibodies were purchased from Cell Signaling
Technology, Inc.: RPTOR (2280), MTOR (2983), RPS6KB
(p70) phospho-(T389) (9206), RPS6KB (p70) (9202), LC3
(2775), ULK1-phospho-(S757) (6888), ULK1 (4773), LMNA
(2032), CCNE1 (4129). GAPDH antibody was bought at
Abcam (ab8245). PLK1 (sc-55504), LAMP2 (sc-18822),
RPTOR phospho-(S863) (sc-130214), and MYC/c-Myc (sc-40)
antibodies for immunoblotting and normal mouse IgG (sc-
2025) and normal rat IgG (sc-2026) for immunoprecipitation
were obtained from Santa Cruz Biotechnology, Inc. H3F3/his-
tone H3 phospho-(S10) (A301–844A) and H3F3/histone H3
(A300–822A) antibodies were bought from Bethyl Laborato-
ries, Inc. The HA antibody (11867423001) was obtained from
Roche. ACTIN (MAB1501) and RPTOR phospho-(S722) (09–
104) antibodies were purchased from Merck Millipore. RPTOR
phospho-(T706), RPTOR phospho-(S859) and RPTOR phos-
pho-(S877)70 were a kind gift from Diane C. Fingar (University
of Michigan Medical School, Ann Arbor, MI, USA). Horserad-
ish peroxidase-conjugated goat anti-mouse (31430) and goat
anti-rabbit IgG (31460) were ordered from Thermo Scientiﬁc
Pierce, horseradish peroxidase-conjugated light chain speciﬁc
antibody for blotting after IP was obtained from Jackson
ImmunoReseach Laboratories, Inc. (115–035–174). For immu-
noﬂuorescence experiments, the RRAGC/RAGC (9480) and
MTOR (2983) antibodies were purchased from Cell Signaling
Technology, Inc., LAMP2 (sc-18822) and PLK1 (sc-17783)
were bought from Santa Cruz, Biotechnology, Inc. The
SQSTM1/p62 antibody was obtained from Progen Biotechnik
(GP62-C). All secondary antibodies for immunoﬂuorescence
experiments were bought from Thermo Fisher Scientiﬁc: Goat
anti-guinea pig IgG (HCL), Alexa Fluor 568 conjugate (A-
11075), goat anti-rabbit IgG (HCL), Alexa Fluor 568 conju-
gate (A-11036), goat anti-rabbit IgG (HCL), Alexa Fluor 488
conjugate (A-11008), goat anti-mouse IgG (HCL), Alexa Flu-
or 488 conjugate (A-11001), and goat anti-mouse IgG (HCL),
Alexa Fluor 568 (A-11004). Baﬁlomycin A1 was bought at
Tebu-Bio (BIA-B1012) and throughout the study used at a ﬁnal
concentration of 100 nM. PLK1 inhibitor BI2536 (Axon Med-
chem, 1129) was used at 100 nM ﬁnal concentration and added
30 min before lysis throughout the study unless otherwise
stated and MTOR inhibitor Torin1 (Axon MedChem, 1833),
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was used at 250 nM and added 30 min before stimulation with
amino acids and insulin.
Cell lysis and immunoblotting
HeLa cells were washed twice with PBS before lysis in RIPA
lysis buffer (1% NP40 [Sigma-Aldrich, I8896], 0.1% sodium
dodecyl sulfate [Sigma-Aldrich, 71725], 0.5% sodium deoxy-
cholate [Sigma-Aldrich, 30970] in PBS) supplemented with
Complete Protease Inhibitor Cocktail (Roche, 11836145001),
Phosphatase Inhibitor Cocktail 2 (Sigma-Aldrich, P5726) and
Cocktail 3 (Sigma-Aldrich, P0044).
Adjustment of the protein concentration, SDS PAGE and
immunoblot were performed as described previously.45 Pierce
ECL western blotting substrate (32209) or SuperSignal West
FEMTO (34095), both from Thermo Scientiﬁc Pierce, were
used to detect chemiluminescence using a LAS-4000 mini cam-
era system (Fujiﬁlm Life Science Systems, Tokyo, JP) or a LAS-
4000 mini camera system (GE Healthcare, Little Chalfont, UK).
Quantiﬁcation of raw image ﬁles was performed using
ImageQuant TL Version 8.1, GE Healthcare. Background sub-
traction was performed using the rolling ball method with a
deﬁned radius of 200 for all images.
For graphical representation, raw images from the Fujiﬁlm
camera were exported as Color TIFF ﬁles using the Fujiﬁlm
software Multi Gauge version 3.0, Fujiﬁlm Life Science Systems,
and further processed with Adobe Photoshop version CS2. Raw
images taken with the LAS-4000 mini, GE Healthcare system
were exported as RGB color TIFF ﬁles using ImageJ, and fur-
ther processed with Adobe Photoshop version CS5.1.
Immunoprecipitation (IP)
HeLa cells were washed 3x with ice-cold PBS and harvested in IP
lysis buffer (40 mM HEPES, 120 mM NaCl and 0.3% CHAPS
[Sigma-Aldrich, 000000010810118001], pH 7.5) supplemented
with Complete (Roche, 11836145001), Phosphatase Inhibitor
Cocktail 2 and Cocktail 3 (Sigma-Aldrich, P5726, P0044). Lysates
were precleaned by adding 10 mL/mL magnetic Dynabeads
Protein G (Life Technologies, 10009D), prewashed in lysis buffer,
for 30 min at 4C with end-over-end rotation. A lysate sample
was taken up in 5x SDS sample buffer (50% glycerol, 5% b-mer-
captoethanol, 0.3 M SDS, 0.03 M Tris, pH 6.8, 0.2 mM bromo-
phenol blue) for subsequent analysis by immunoblot. IP was
performed by adding 7.5 mg of a speciﬁc antibody or control
IgG (“mock,” negative control) per mL lysate for 30 min at 4C.
Subsequently, 37.5 mL prewashed Dynabeads Protein G per
mL lysate were added to the IP reactions for 1.5 h at 4C. Beads
were washed 3 times brieﬂy and twice for 10 min in IP lysis
buffer and resuspended in 1x SDS sample buffer.
PLK1 kinase assay
HeLa cells were transfected with pRK5-HA-RPTOR (Addgene
plasmid 8513,52 gift from David Sabatini) 48 h before the experi-
ment. HA-RPTOR was immunopuriﬁed using an HA antibody. A
control (mock) IP was performed with rat IgG. The immunopreci-
pitates were dephosphorylated with alkaline phosphatase (10 U;
Thermo Scientiﬁc, EF0652) for 1 h at 37C, and washed with IP
lysis buffer, followed by a washing step with kinase assay buffer
(20 mM HEPES, pH 7,4, 150 mM KCl, 10 mMMgCl2). Recombi-
nant PLK1 (0.1 mg; Enzo Life Sciences, BML-SE466–0005) was
added to RPTOR and mock IPs as indicated. The kinase-substrate
mixture was preincubated on ice for 15min with BI2536 (100 nM),
Torin1 (250 nM) or carrier, respectively. An ATP mix with 1 mM
cold ATP (GE Healthcare, 27–1006–01) and 5 to 10 mCi [g-33P]
ATP (PerkinElmer, NEG302H250UC) was added and incubated
for 30 min at 30Cwith gentle shaking. Samples were washed once
with kinase assay buffer before resuspension in 1x SDS sample
buffer and heated for 15 min at 68C. Samples were separated by
SDS-PAGE and phosphorylation was analyzed by autoradiogra-
phy. For quantiﬁcation the signal that was measured for the condi-
tion without PLK1 was considered as background and thus
subtracted. For nonradioactive assay the same protocol was per-
formed, 0.4 mM cold ATP was added and samples were analyzed
by immunoblotting.
Sucrose gradient
HeLa cells were treated as indicated and lysed in homogeniza-
tion buffer (50 mM Tris-HCl, pH 7.4, 250 mM sucrose [Sigma-
Aldrich, S2395], 25 mM KCl, 5 mM MgCl2, 3 mM imidazole),
supplemented with Complete (Roche, 11836145001) and Phos-
phatase Inhibitor Cocktail 2 and Cocktail 3 (Sigma-Aldrich,
P5726, P0044). Plates were incubated for 30 min on a rocking
platform at 4C. Subsequently, cells were scraped and centri-
fuged at 12,000 g for 10 min at 4C. The supernatant was trans-
ferred to a new tube and the protein concentration was
determined using Bradford assay. Protein (1.5 mg) was loaded
on a sucrose gradient. A continuous gradient was prepared
from 10% to 40% sucrose using an ultracentrifuge tube with a
total volume of 4 mL. Lysates were distributed in the sucrose
gradient using ultracentrifugation (194,000 g, at least 16 h,
Beckman SW55 Ti rotor, Brea, California, USA). After centrifu-
gation, each sample was divided into 12 fractions and taken up
in 5x loading buffer. Samples were analyzed by immunoblot.
Quantiﬁcation was performed by determination of the relative
intensities of PLK1 positive signals. The percentage of PLK1 in
a certain fraction was calculated by determining the ratio
between the relative intensity in a single lane and the relative
intensity of the sum of all PLK1-positive signals. The percent-
age of PLK1 in either the lysosomal or the nuclear fraction was
calculated by addition of normalized PLK1 in LAMP2 or H3F3
and LMNA positive lanes, respectively.
Immunoﬂuorescence microscopy
For all immunoﬂuorescence experiments, cells were washed in
PBS and ﬁxed with 4% paraformaldehyde in PBS for 20 min at
room temperature. After washing the cells 3 times with PBS,
permeabilization was performed as indicated. Cells were
washed in PBS and blocked with 0.3% bovine serum albumin
(Carl Roth, 8076.5) or 0.3% FCS in PBS, as indicated. Hoechst
33342 (end concentration 1 mg/mL; Invitrogen, H3570) was
added and incubated for 30 min in the dark at room tempera-
ture. Cells were mounted with Mowiol 4–88 (Carl Roth, 07131)
solution, which was prepared according to the manufacturer’s
instructions including DABCO (1,4-diazabicyclo[2.2.2]octane;
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Sigma-Aldrich, D27802) supplemented with 10% n-propyl-gal-
late (NPG; VWR International, 8.205.990.100), and analyzed
using ﬂuorescence microscopy.
For colocalization analysis of MTOR-LAMP2, MTOR-PLK1,
and RRAGC-LAMP2 permeabilization was performed with 0.1%
Triton X-100 (Sigma Aldrich, 93443) in PBS for 1 min and cells
were blocked with 0.3% FCS in PBS. Z stack images were taken
with an AxioObserver Z1 compound microscope (Carl Zeiss,
Oberkochen, Germany) with an Apotome, 63x objective (Carl
Zeiss, Oberkochen, Germany) and anAxioCamMRm3CCD cam-
era (Zeiss, Oberkochen, Germany). For quantitative analysis, 4 or 5
representative ﬁelds of view were captured for each condition with
identical exposure times and the same magniﬁcation. The Pearson
correlation coefﬁcient was calculated across raw ﬁles, without any
image processing, using the colocalization module of the Zen soft-
ware (Zen2012 blue edition software, Zeiss) after automatically set-
ting the threshold with the Costes method. For presentation in
ﬁgures, single layers of representative raw Z stacks were exported
as TIFF with no compression using Zen2012 blue edition software
(Zeiss) and brightness or contrast were adjusted, for better visibil-
ity. Brightness or contrast adjustment was not performed before
quantiﬁcation, and thus did not inﬂuence image quantiﬁcation.
PLK1 staining in mitotic cells was performed after prometa-
phase arrest and a release of 30 min in full medium. Mitotic
cells were collected by centrifugation (500 g, 4 min). PFA-ﬁxed
cells were permeabilized with 0.1% Triton X-100 in PBS for
1 min and cells were blocked with 0.3% FCS in PBS.
To monitor autophagosomes and autolysosomes an mRFP-
GPF-LC3 tandem construct61 (Addgene, plasmid 21074, gift
from Tamotsu Yoshimori). Cells were grown on coverslips, and
transfected with the mRFP-GFP-LC3 plasmid. After 48 h cells
were ﬁxed as described above. Permeabilization was performed
with 0.1% Triton X-100 in PBS for 30 to 45 s and 0.3% bovine
serum albumin was used for blocking. Images were taken with
an AxioImager Z1 compound microscope from Zeiss, 63x
objective and an AxioCam MRm3 CCD camera. Prior to quan-
tiﬁcation images were deconvoluted using Huygens software,
Huygens remote manager v3.0.3 (Scientiﬁc Volume Imaging).
For image parameters a pixel size of 60 nm was assumed. For
processing parameters the classic maximum likelihood estima-
tion deconvolution algorithm was chosen and the signal/noise
ratio was set to 90 for all channels. The number of green and
red puncta was counted using the spot detection function of
Imaris Version 7.7.2 (BITPLANE AG). The background sub-
traction was ticked. As ﬁlter type, quality above threshold was
chosen. Within one experiment the threshold and the estimated
xy diameter were kept equal for all analyzed images. To deter-
mine the percentage of autolysosomes per cell, we counted red
and green puncta, and subsequently calculated the difference
between mRFP and GFP puncta, which we expressed as the
percentage of all red puncta per cell. At least 25 nonmitotic
cells, as judged by Hoechst staining, were counted per condi-
tion. For presentation in ﬁgures, representative raw images
were exported as TIFF with no compression using Zen2012
blue edition software (Zeiss) and brightness or contrast were
adjusted, for better visibility. Images are shown without prior
deconvolution. Brightness or contrast adjustment was not per-
formed before quantiﬁcation, and thus did not alter the num-
bers of quantiﬁed green and red puncta.
For the SQSTM1 staining, permeabilization was performed
with 1% saponin (Sigma Aldrich, 47036) for 15 min and cells
were blocked with 0.3% FCS in PBS. Z stack images were taken
with an AxioObserver Z1 compound microscope with Apo-
tome from Zeiss, 63x objective, AxioCam MRm3 CCD camera.
For quantitative analysis, at least 5 representative ﬁelds of view
were captured for each condition with identical exposure times
and the same magniﬁcation. The total area of SQSTM1/p62
positive foci was calculated using ImageJ 1.47v. The threshold
was set manually and kept identical for comparative analysis
before applying the “Analyze Particles” function. The total area
was normalized to the number of nuclei.
For presentation in ﬁgures, maximum intensity projections
of representative raw images were exported as TIFF with no
compression using Zen2012 blue edition software (Zeiss) and
brightness or contrast were adjusted, for better visibility.
Brightness or contrast adjustment was not performed before
quantiﬁcation, and thus did not inﬂuence image quantiﬁcation.
C. elegans experiments
The C. elegans strain MAH14 (daf-2(e1370); adIs2122[lgg-1p::
gfp::lgg-1 Crol-6]64) was used for this study. The strain was
maintained at 20C and raised on NGM plates seeded with
Escherichia coli strain OP50 as described previously.75 To inves-
tigate autophagy, eggs from MAH14 animals were transferred
to RNAi plates (atg-18 RNAi clone was from the Vidal
library,76 and plk-1 RNAi clone was from the Ahringer
library77) and incubated at 25C to induce dauers. Following
incubation for 6 d, dauers were anesthetized with sodium azide,
arranged vertically on agar plates and imaged using an AxioIm-
ager Z1 compound microscope ﬁtted with an AxioCam MRm3
CCD camera. GFP intensity was quantiﬁed using Image J soft-
ware and normalized to the size of the animals.
Statistics
Quantiﬁcations of experiments were displayed and statistically
analyzed using GraphPad Prism Version 5.00. For all experi-
ments in human cells, the mean and the standard error of the
mean (SEM) were plotted. For quantiﬁcation of GFP::LGG-1
ﬂuorescence in C. elegans the mean and the standard deviation
(s. d.) were plotted. Two groups were compared using a non-
parametric 2-tailed Student t test assuming unequal variances.
For comparison of multiple groups, a one-way ANOVA fol-
lowed by the Bonferroni multiple comparison test was used. P
values below 0.05 were considered signiﬁcant.
Abbreviations
aa amino acids




BSA bovine serum albumin
CCNE1 cyclin E1
C. elegans Caenorhabditis elegans
CID collision-induced dissociation
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DABCO 1,4-diazabicyclo[2.2.2]octane
DMEM Dulbecco’s modiﬁed Eagle’s medium
DNA deoxyribonucleic acid
GAP GTPase activating protein
GAPDH glyceraldehyde-3-phosphate
dehydrogenase
GFP green ﬂuorescent protein
H3F3 H3 histone family member 3






LAMP2 lysosomal associated membrane pro-
tein 2
LMNA lamin A/C
MAP1LC3A/LC3A microtubule associated protein 1
light chain 3 a
mRFP monomeric red ﬂuorescent protein
MS mass spectrometry
MTOR mechanistic target of rapamycin
MTORC1 MTOR complex 1




PLK1 polo like kinase 1
RHEB Ras homolog enriched in brain




RPS6 ribosomal protein S6
RPS6KA1/RSK ribosomal protein S6 kinase A1
RPS6KB (p70)/p70-S6K ribosomal protein S6 kinase B 70 kDa
RPS6KB (p85)/p85-S6K ribosomal protein S6 kinase B
85 kDa
RPTOR/RAPTOR regulatory associated protein of
MTOR complex 1
RRAGC/RAGC Ras related GTP binding C
s. d. standard deviation
SDS sodium dodecyl sulfate
SEM standard error of the mean
shRNA small hairpin RNA
SILAC stable isotope labeling by amino
acids in cell culture
siRNA small interference RNA
SQSTM1/p62 sequestosome 1
TSC1 tuberous sclerosis 1
TSC2 tuberous sclerosis 2
ULK1 unc-51 like autophagy activating
kinase 1
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